Skip to main content
Erschienen in: Journal of Endocrinological Investigation 7/2023

01.07.2023 | Original Article

The potent contraceptive gestodene exerts insulinotropic effects through its a-ring reduced metabolites with intrinsic estrogen-like activity in pancreatic β-cells

verfasst von: J. Enríquez, T. Sosa-Larios, E. Díaz-Díaz, S. Morimoto

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The contraceptive gestodene is a potent synthetic progestin used in several low-dose contraceptive formulations. Clinical studies reported a relationship between long-term use of combined oral contraceptives containing gestodene (GDN) and profound alterations in glucose metabolism in women. The observation that contraceptive synthetic progestins exert hormone-like effects other than their progestational activities, prompted us to investigate whether GDN may induce estrogen-like effects, even though GDN does not interact with estrogen receptors. The aim of this study was to investigate whether GDN affect pancreatic β-cell activity, directly or through its conversion to other bioactive metabolites.

Methods

The effects of GDN and its two derivatives 3β,5α-tetrahydro-GDN and 3α,5α-tetrahydro-GDN on insulin 2 (Ins II) and glucokinase (Gk) expression and glucose-stimulated insulin secretion were determined in pancreatic islets from female rats.

Results

Gestodene did exert significant effects on islet β-cells activity. The most striking finding was that 3β,5α-tetrahydro-GDN and 3α,5α-tetrahydro-GDN had greater stimulatory effects on Ins II and Gk expression than that observed with GDN, consistent with their effects on glucose-stimulated insulin secretion. The effects on gene expression induced by GDN-derivatives were abolished by ICI 182,780 and MPP. In addition, the presence of inhibitors of androgen and progestin-metabolizing enzymes eliminated gene expression induced by GDN. These results indicated that GDN is metabolized to A-ring reduced metabolites with estrogen-like activities and through this mechanism, GDN may affect β-cell activity.

Conclusions

Altogether, the data suggest that 19-nortestosterone-derived contraceptives such as GDN, possess insulinotropic effects through their conversion into metabolites with intrinsic estrogen-like activity in pancreatic β-cells.
Literatur
1.
Zurück zum Zitat Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRefPubMed Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRefPubMed
3.
Zurück zum Zitat Liu S, Mauvais-Jarvis F (2010) Minireview: estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 151:859–864CrossRefPubMed Liu S, Mauvais-Jarvis F (2010) Minireview: estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 151:859–864CrossRefPubMed
4.
Zurück zum Zitat Doglioni C, Gambacorta M, Zamboni G, Coggi G, Viale G (1990) Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. Am J Pathol 137:999–1005PubMedPubMedCentral Doglioni C, Gambacorta M, Zamboni G, Coggi G, Viale G (1990) Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. Am J Pathol 137:999–1005PubMedPubMedCentral
5.
Zurück zum Zitat Winborn WB, Sheridan PJ, McGill HC Jr (1987) Localization of progestin receptors in the islets of Langerhans. Pancreas 2:289–294CrossRefPubMed Winborn WB, Sheridan PJ, McGill HC Jr (1987) Localization of progestin receptors in the islets of Langerhans. Pancreas 2:289–294CrossRefPubMed
6.
Zurück zum Zitat Kalkhoff RK, Jacobson M, Lemper D (1970) Progesterone, pregnancy and the augmented plasma insulin response. J Clin Endocrinol Metab 3:24–28CrossRef Kalkhoff RK, Jacobson M, Lemper D (1970) Progesterone, pregnancy and the augmented plasma insulin response. J Clin Endocrinol Metab 3:24–28CrossRef
7.
Zurück zum Zitat Nielsen JH (1984) Direct effect of gonadal and contraceptive steroids on insulin release from mouse pancreatic islets in organ culture. Acta Endocrinol (Copenh) 105:245–250PubMed Nielsen JH (1984) Direct effect of gonadal and contraceptive steroids on insulin release from mouse pancreatic islets in organ culture. Acta Endocrinol (Copenh) 105:245–250PubMed
8.
Zurück zum Zitat Dong F, Ling Q, Ye D, Zhang Z, Shu J, Chen G, Fei Y, Li C (2016) TCF7L2 involvement in estradiol- and progesterone-modulated islet and hepatic glucose homeostasis. Sci Rep 6:248–259 Dong F, Ling Q, Ye D, Zhang Z, Shu J, Chen G, Fei Y, Li C (2016) TCF7L2 involvement in estradiol- and progesterone-modulated islet and hepatic glucose homeostasis. Sci Rep 6:248–259
9.
Zurück zum Zitat Zhou R, Yao X, Xu X, Wang G, Zhu Z, Chen J, Chen L, Shen X (2013) Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability. Steroids 78:987–995CrossRefPubMed Zhou R, Yao X, Xu X, Wang G, Zhu Z, Chen J, Chen L, Shen X (2013) Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability. Steroids 78:987–995CrossRefPubMed
10.
Zurück zum Zitat Picard F, Wanatabe M, Schoonjans K, Lydon J, O’Malley BW, Auwerx J (2002) Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta-cell proliferation. Proc Natl Acad Sci U S A 99:15644–15648CrossRefPubMedPubMedCentral Picard F, Wanatabe M, Schoonjans K, Lydon J, O’Malley BW, Auwerx J (2002) Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta-cell proliferation. Proc Natl Acad Sci U S A 99:15644–15648CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kaplan B (1995) Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 29:736–742CrossRefPubMed Kaplan B (1995) Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 29:736–742CrossRefPubMed
13.
Zurück zum Zitat Stanczyk FZ, Archer DF (2014) Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception 89:242–252CrossRefPubMed Stanczyk FZ, Archer DF (2014) Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations. Contraception 89:242–252CrossRefPubMed
14.
Zurück zum Zitat Spona J, Huber J (1987) Efficacy of low-dose oral contraceptives containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet Invest 23:184–193CrossRefPubMed Spona J, Huber J (1987) Efficacy of low-dose oral contraceptives containing levonorgestrel, gestodene and cyproterone acetate. Gynecol Obstet Invest 23:184–193CrossRefPubMed
15.
Zurück zum Zitat van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft CA (1999) Comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 4:27–35CrossRefPubMed van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft CA (1999) Comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 4:27–35CrossRefPubMed
16.
Zurück zum Zitat van der Vange N, Kloosterboer HJ, Haspels AA (1987) Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 156:918–922CrossRefPubMed van der Vange N, Kloosterboer HJ, Haspels AA (1987) Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 156:918–922CrossRefPubMed
17.
Zurück zum Zitat Spellacy WN, Tsibris AMN, Tsibris JCM, George S, Chez RA, O’Brien WF (1994) Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol. Contraception 49:125–130CrossRefPubMed Spellacy WN, Tsibris AMN, Tsibris JCM, George S, Chez RA, O’Brien WF (1994) Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol. Contraception 49:125–130CrossRefPubMed
18.
Zurück zum Zitat Lemus AE, Santillán R, Damián-Matsumura P, García GA, Grillasca I, Pérez-Palacios G (2001) In vitro metabolism of gestodene in target organs: formation of A-ring reduced derivatives with oestrogenic activity. Eur J Pharmacol 417:249–256CrossRefPubMed Lemus AE, Santillán R, Damián-Matsumura P, García GA, Grillasca I, Pérez-Palacios G (2001) In vitro metabolism of gestodene in target organs: formation of A-ring reduced derivatives with oestrogenic activity. Eur J Pharmacol 417:249–256CrossRefPubMed
19.
Zurück zum Zitat Lemus AE, Zaga V, Santillán R, García GA, Grillasca I, Damián-Matsumura P, Jackson KJ, Cooney AJ, Larrea F, Pérez-Palacios G (2000) The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. J Endocrinol 165:693–702CrossRefPubMed Lemus AE, Zaga V, Santillán R, García GA, Grillasca I, Damián-Matsumura P, Jackson KJ, Cooney AJ, Larrea F, Pérez-Palacios G (2000) The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites. J Endocrinol 165:693–702CrossRefPubMed
20.
Zurück zum Zitat Enríquez J, García G, Herrero B, Larrea F (2017) The synthetic progestin, gestodene, affects functional biomarkers in neonatal rat osteoblasts through an estrogen receptor-related mechanism of action. Endocr Res 42:269–280CrossRefPubMed Enríquez J, García G, Herrero B, Larrea F (2017) The synthetic progestin, gestodene, affects functional biomarkers in neonatal rat osteoblasts through an estrogen receptor-related mechanism of action. Endocr Res 42:269–280CrossRefPubMed
21.
Zurück zum Zitat Düstenberg B, Tack JW, Jrause W, Humpel M (1987) Pharmacokinetics and biotransformation of gestodene in man. In Gestodene. Development of a New Gestodene-containing Low Dose Oral Contraceptive, pp 35–44. Ed M Elstein. Carnforth, Lancs, UK Parthenon Düstenberg B, Tack JW, Jrause W, Humpel M (1987) Pharmacokinetics and biotransformation of gestodene in man. In Gestodene. Development of a New Gestodene-containing Low Dose Oral Contraceptive, pp 35–44. Ed M Elstein. Carnforth, Lancs, UK Parthenon
22.
Zurück zum Zitat Zatroch KK, Knight CG, Reimer JN, Pang DS (2017) Refinement of intraperitoneal injection of sodium pentobarbital for euthanasia in laboratory rats (Rattus norvegicus). BMC Vet Res 13:60CrossRefPubMedPubMedCentral Zatroch KK, Knight CG, Reimer JN, Pang DS (2017) Refinement of intraperitoneal injection of sodium pentobarbital for euthanasia in laboratory rats (Rattus norvegicus). BMC Vet Res 13:60CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39CrossRefPubMed Lacy PE, Kostianovsky M (1967) Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16:35–39CrossRefPubMed
24.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408CrossRefPubMed
25.
Zurück zum Zitat Jiménez IU, Díaz-Díaz E, Castro JS, Ramos JP, León MC, Alvarado Ríos JA, Auriostigue Bautista JC, Correa-Rotter R, Aguilar Salinas CA, Larrea F (2017) Circulating concentrations of advanced glycation end products, its association with the development of diabetes mellitus. Arch Med Res 48:360–369CrossRefPubMed Jiménez IU, Díaz-Díaz E, Castro JS, Ramos JP, León MC, Alvarado Ríos JA, Auriostigue Bautista JC, Correa-Rotter R, Aguilar Salinas CA, Larrea F (2017) Circulating concentrations of advanced glycation end products, its association with the development of diabetes mellitus. Arch Med Res 48:360–369CrossRefPubMed
26.
Zurück zum Zitat Wong WP, Tiano JP, Liu S, Hewitt SC, Le May C, Dalle S, Katzenellenbogen JA, Katzenellenbogen BS, Korach KS, Mauvais-Jarvis F (2010) Extranuclear estrogen receptor-alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci U S A 107:13057–13062CrossRefPubMedPubMedCentral Wong WP, Tiano JP, Liu S, Hewitt SC, Le May C, Dalle S, Katzenellenbogen JA, Katzenellenbogen BS, Korach KS, Mauvais-Jarvis F (2010) Extranuclear estrogen receptor-alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci U S A 107:13057–13062CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Larrea F, García-Becerra R, Lemus AE, García GA, Pérez-Palacios G, Jackson KJ, Coleman KM, Dace R, Smith CL, Cooney AJ (2001) A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ERα. Endocrinology 142:3791–3799CrossRefPubMed Larrea F, García-Becerra R, Lemus AE, García GA, Pérez-Palacios G, Jackson KJ, Coleman KM, Dace R, Smith CL, Cooney AJ (2001) A-ring reduced metabolites of 19-nor synthetic progestins as subtype selective agonists for ERα. Endocrinology 142:3791–3799CrossRefPubMed
28.
Zurück zum Zitat Xu W, Schiffer L, Qadir MMF, Zhang Y, Hawley J, Mota De Sa P, Keevil BG, Wu H, Arlt W, Mauvais-Jarvis F (2020) Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion. Diabetes 69:2392–2399CrossRefPubMedPubMedCentral Xu W, Schiffer L, Qadir MMF, Zhang Y, Hawley J, Mota De Sa P, Keevil BG, Wu H, Arlt W, Mauvais-Jarvis F (2020) Intracrine testosterone activation in human pancreatic β-cells stimulates insulin secretion. Diabetes 69:2392–2399CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Iqbal MJ, Greenway B, Wilkinson ML, Johnson PJ, Williams R (1983) Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin Sci (Lond) 65:71–75CrossRefPubMed Iqbal MJ, Greenway B, Wilkinson ML, Johnson PJ, Williams R (1983) Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin Sci (Lond) 65:71–75CrossRefPubMed
30.
Zurück zum Zitat Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquié M, Gauthier BR, Nef S, Stefani E, Nadal A (2008) Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS ONE 3:e2069CrossRefPubMedPubMedCentral Alonso-Magdalena P, Ropero AB, Carrera MP, Cederroth CR, Baquié M, Gauthier BR, Nef S, Stefani E, Nadal A (2008) Pancreatic insulin content regulation by the estrogen receptor ER alpha. PLoS ONE 3:e2069CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Zhang L, Zhao Y, Guo L (2018) 17β-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway. Int J Mol Med 41:2839–2846PubMed Zhang L, Zhao Y, Guo L (2018) 17β-estradiol protects INS-1 insulinoma cells from mitophagy via G protein-coupled estrogen receptors and the PI3K/Akt signaling pathway. Int J Mol Med 41:2839–2846PubMed
Metadaten
Titel
The potent contraceptive gestodene exerts insulinotropic effects through its a-ring reduced metabolites with intrinsic estrogen-like activity in pancreatic β-cells
verfasst von
J. Enríquez
T. Sosa-Larios
E. Díaz-Díaz
S. Morimoto
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 7/2023
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-022-01977-2

Weitere Artikel der Ausgabe 7/2023

Journal of Endocrinological Investigation 7/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.